poudre pour solution injectable (IM-IV)
Sponsors
Lysarc, Assistance Publique Hopitaux De Paris, Centre Hospitalier De Versailles, Centre Hospitalier Universitaire De Nantes, University Hospital Of Clermont-Ferrand
Conditions
Breast CancerCOPD : chronic obstructive Pulmonary diseaseCommunity-acquired pneumoniaPeripheral T-cell lymphoma (PTCL)staphylococcal endocarditis
Phase 3
CUSTOMIZED ANTIBIOTIC TREATMENT DURATION AMONG HOSPITALIZED PATIENTS WITH MODERATELY SEVERE COMMUNITY-ACQUIRED PNEUMONIA [CAT-CAP]
RecruitingCTIS2023-504208-27-00
Start: 2024-02-12Target: 424Updated: 2025-04-10
CORTICOP_Comparison of corticosteroids versus placebo on duration of ventilatory support during severe acute exacerbations of COPD patients in the intensive care unit: a multicentre randomized controlled trial
Active, not recruitingCTIS2024-516651-41-00
Start: 2021-10-08Target: 440Updated: 2025-09-23
Rifampin-free regimen versus rifampin-containing regimen in the treatment of staphylococcal prosthetic valve endocarditis: a multicenter randomized controlled non-inferiority study (RIFREE)
Not yet recruitingCTIS2024-518018-22-00
Target: 422Updated: 2025-08-28
PROPHY-SEIN - Evaluation of the effect of antibiotic prophylaxis during lumpectomy for breast cancer: prospective randomised double-blind noninferiority study of placebo vs cefazolin
Not yet recruitingCTIS2025-525020-99-00
Target: 1600Updated: 2026-07-16